Satellos Bioscience

Satellos Biotech announced at the Cantor Healthcare conference that two phase‑II studies in Duchenne muscular dystrophy (BASECAMP and TRAILHEAD) are expected to produce important data in the coming months. Phase‑I data showed no concerning safety profile and early signs of efficacy, including a notable increase in handgrip strength in some adults. The company also plans a phase‑II study in FSHD before year‑end and sees regulatory pathways for accelerated approvals based on objective biomarkers. The stock reacted positively but remains dependent on the success of the studies and the quality of the data. » Plus sur de.investing.com

Satellos appoints Antoinette Paone as chief development officer and head of regulatory affairs to advance development of its therapies for muscle diseases. Paone joins from Generation Bio, where she was most recently chief operating officer, and brings experience from a ten-year tenure at Vertex, where she led approval programs for cystic fibrosis therapies. Satellos is pursuing the orally administered agent SAT-3247 as a treatment for Duchenne muscular dystrophy; ongoing clinical trials in adults and children are intended to bring it closer to potential approval. » Plus sur de.investing.com